Home
NewsNewsThe Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
On April 16, 2026, Ferring Pharmaceuticals and Gallup announced the launch of the Ferring Global Fertility Monitor at the 2026 Annual Convening of Semafor World Economy in Washington, D.C. Integrated into the Gallup World Poll, the study will collect data from representative samples across 70 countries to identify the social, economic, and structural factors influencing fertility decisions. The initiative addresses a global decline in total fertility rates, which have fallen below replacement levels in many nations, including record lows recently reported in the United States.
The project Ferring Global Fertility Monitor begins this year with expert consultations and a research process designed to identify critical evidence gaps. A tested questionnaire will be added to the 2027 Gallup World Poll and will function as a biannual tracker. Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer of Ferring Pharmaceuticals, said: “As a company committed to supporting people on their fertility journey, we see the global debate on demographic change as one of the defining issues of our time. Around the world, questions about the future shape of populations are intensifying, yet the data needed to fully understand these shifts and their implications remains far too limited. This project has the potential to transform that landscape. By strengthening the global evidence base, we can deepen understanding of what is happening and why, helping governments, health systems and communities plan for a more sustainable future.”
Leveraging Gallup’s survey infrastructure, which covers approximately 140 countries, the monitor will utilize face-to-face and telephone interviews to gather nationally representative data from adult populations. Jon Clifton, Chief Executive Officer of Gallup, said: “We spend a lot of time debating falling fertility and birth rates, but surprisingly little time asking people why. This initiative changes that, using nationally representative data, collected consistently at a scale no one has attempted before across 70 countries.” The resulting evidence base is intended to assist policymakers in understanding the cultural and social drivers behind parenthood aspirations and the factors that impact their realisation.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
INVO Fertility, Inc has confirmed that its Wisconsin Fertility Institute-WFI clinic joined the Progyny network, making advanced reproductive care more widely available and accessible for more patients seeking fertility treatment.
Births resulting from essential Infertility Treatments, including advanced procedures like artificial insemination and IVF, have seen a very positive and promising climb, accounting for almost 15.1% of the total births recorded in 2024.
The Fertility Society of Ghana has urged the government to officially recognize infertility as a disease and include basic fertility services in the National Health Insurance Scheme during its eighth Annual General meeting, held in Tema.
